Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE boosted as group strengthens patent hold on Parsortix

Shares in ANGLE nudged up at the start of the week as the group strengthened the protection over its blood cell separation technology - unveiling a second US patent.
ANGLE boosted as group strengthens patent hold on Parsortix

Shares in ANGLE (LON:AGL) nudged up at the start of the week as the group strengthened the protection over its blood cell separation technology - unveiling a second US patent.

This patent strengthens the claims for Parsortix protected by the first, ANGLE said, and similar patents have now been issued worldwide for the system, which captures cells for medical analysis.

The device allows for the early detection of cancer and could be a significant step forward in the fight against the killer disease.

The latest patent protects certain aspects of the design and manufacture of the technology for wider useage, and includes cell detection, identification and analysis directly on devices after they have been captured.

It also covers separting specific cells including foetal and stem cells as well as the circulating tumour cells.

The medtech specialist's founder and chief  executive Andrew Newland told investors on Monday: "The grant of our second US patent gives ANGLE broader protection over the Parsortix separation technology. 

"We are pursuing a strategy to strengthen the breadth and duration of our patent coverage to maximise the commercial returns that can be achieved from our Parsortix technology."

He told Proactive that future big catalysts for the firm included pilot studies of Parsortix for medical applications and FDA authorisation.

Navid Malik, head of life science research at broker Cenkos, welcomed the latest patent, saying it had "high commercial significance" as it extended both the duration and the scope of the current level of patent protection, and provided added endorsement  of the Parsortix technology. 

"We await further news flow surrounding the completion of corresponding patent applications in other geographic markets and reiterate our BUY rating."

In its finals last month, the firm said 2014 financial year had been one of significant progress and it was now focused on establishing using the system in clinical practice.

Highlights of the year included a CE mark authorisation for Parsortix to be used as an in vitro device in clinical use in the European Union.

The firm also made an FDA 510(k) submission in March this year for the clinical use of Parsortix system in the US.

The loss for the year was £1.2 million (2013: loss £1 million) and the cash balance as at April 30 was £3.9mln.

Shares rose 1.99% to stand at 77 pence each.

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use